Galnobax®

About NovaLead Pharma

NovaLead Pharma is a private, venture-backed biotech founded in 2016, leveraging a proprietary in-silico drug repositioning platform to discover new therapeutic uses for generic drugs. Its most advanced program, Galnobax® for Diabetic Foot Ulcer, has met primary and secondary endpoints in Phase III, leading to a recent out-licensing deal with Ipca Laboratories for the Indian market. The company's pipeline includes additional candidates like NLP91 for psoriasis, targeting a combined addressable market estimated at over $10 billion annually. NovaLead's model is to out-license discoveries after proof-of-concept, minimizing late-stage safety risks.

Therapeutic Areas